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EDITORIAL
Taking HAART in HIVAN: Will protease inhibitor sparing
regimens alter renal outcome?
Highly active antiretroviral therapy (HAART) is reno-
protective in HIV-associated nephropathy (HIVAN).
The basis of this protection is complex, as both HIV
reverse-transcriptase inhibitors and HIV protease in-
hibitors (PIs) have biologic actions independent of their
antiviral effects. A new study by Mongia et al [1] in this
issue of Kidney International shows that the PI saquinavir
significantly blocks reactive oxygen species (ROS) gener-
ation and ROS-linked apoptosis in mouse mesangial cells
independent of HIV gene expression. Thus, HAART
modulation of renal injury may transcend its antiviral
effects.
Insight into HIVAN pathogenesis has emerged from
study of patient renal biopsies and transgenic mice
bearing noninfectious HIV-1 DNA constructs. Renal
parenchymal cell infection and expression of HIV-1 genes
are crucial to disease initiation [2]. Epithelial cell prolif-
eration and apoptosis triggered by viral products in turn
precipitate sclerosing mechanisms. The role of viral per-
sistence in progression is unknown; however, renal ep-
ithelium is a reservoir for latent infection, and renal viral
replication can persist in the face of an undetectable sys-
temic viral load.
Preliminary reports indicate that HAART has benefi-
cial effects on the prevalence and progression of HIVAN
[3]. Suppression of viral replication is clearly a key factor
in improved outcomes. Less appreciated are the poten-
tial disease-modulating nonvirologic actions of HAART,
in particular anti-apoptotic effects of PIs. Programmed
cell death plays a key role in pathogenesis and progres-
sion of HIV infection, as HIV-encoded proteins regulate
host cell apoptosis through multiple pathways [4]. Apop-
totic depletion of CD4 T-cells has devastating clinical
consequences, and replenished CD4 counts, as well as re-
duced viral load, are the principal barometers of HAART
efficacy.
HAART has complex effects on immune cell death.
Both the reverse-transcriptase inhibitor zidovudine
(AZT) and PIs target T-cell mitochondria, but with op-
posite effects. AZT inhibits oxidative phosphorylation
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to promote apoptosis, whereas PIs stabilize activated
T-cell mitochondrial membrane potential to inhibit cell
cycle progression and apoptosis [5]. In doing so PIs ef-
fectively counter AZT cytotoxicity. The antiapoptotic ef-
fects of PIs have been linked to reduced production of
ROS, mediators known to create a permissive environ-
ment for caspase activation. PIs are also reported to alter
death receptor and caspase 1 expression and cell acti-
vation. Patients receiving PI-based therapy consistently
demonstrate rapid and significant declines in T-cell apop-
tosis, irrespective of antiviral outcome. This finding is
reproduced in vitro by PI treatment of T-cells from HIV-
infected and uninfected individuals, and is also described
for CD34+ stem cells and polymorphonuclear leukocytes
[6]. Effects are dose-dependent and manifest at PI con-
centrations suboptimal for antiviral effect.
Do PIs have nonviral effects in HIVAN pathogene-
sis and progression? While the answer is unknown, these
processes are ripe for modulation by metabolic actions of
PIs. Epithelial cell proliferation and apoptosis are well-
documented features of HIVAN, and in vitro HIV-1 in-
fection causes rapid apoptosis of tubular epthelial cells
[7]. Mesangial hypercellularity, matrix accumulation, and
ultimately sclerosis are consistent features of HIVAN.
Although it is unresolved whether human or mouse
mesangial cells are naturally susceptible to direct
HIV infection, HIV patient serum has been demon-
strated to bolster mesangial cell proliferation [8]. In
nonviral rodent models of mesangioproliferative dis-
ease, mesangial cell apoptosis is a homeostatic mech-
anism. Unregulated apoptosis causes excessive cell
dropout.
In an accompanying article in this issue of Kidney Inter-
national Mongia et al [1] demonstrate viral-independent
antiapoptotic and ROS-scavenging effects of PIs on
mouse mesangial cells in vitro. This protection extends
to the exaggerated mesangial apoptosis induced by
HIV gene expression and recreational drug metabolites.
Mesangial protection involves free radical scavenging ac-
tions of PIs, but the role of oxidant stress is complicated.
Saquinavir protects mesangial cells from apoptosis in
three different models of ROS-induced injury, but fails
to protect against nitric oxide (NO) triggered cell death.
ROS and NO signals are known to overlap and pro-
duce antagonistic as well as synergistic effects, and
intricate ROS/NO interactions have been reported in
1105
1106 Editorial
mesangial cells. This may explain the unexpected find-
ing by Mongia et al that a seven-fold induction of heme
oxygenase-1 (HO-1) by hemin not only fails to pro-
tect, but rather enhances ROS-induced mesangial cell
apoptosis. HO-1 is the rate-limiting enzyme that cat-
alyzes the degradation of pro-oxidant heme into iron,
carbon monoxide, and biliverdin, which is subsequently
metabolized to the potent antioxidant bilirubin. HO-1 is
induced in states of oxidant stress in most cells and is
best known for its powerful antioxidant and antiapop-
totic actions. There is evidence, however, that HO-1 reg-
ulation of apoptosis is cell-specific. Adenoviral-mediated
overexpression of HO-1 induces apoptosis in vascular
smooth muscle cells, possibly via bilirubin- and biliverdin-
mediated up-regulation of a p53-dependent pathway [9].
Notably, p53 accumulation in response to NO is linked
to apoptosis, and a cytotoxic role for NO-induced HO-1
in mesangial cells has been posited [10]. How these path-
ways engage in HIVAN is unknown. Regulation of NO
production is differentially altered in acute versus chronic
HIV infection, and whereas systemic oxidative stress is
a common feature of HIV and other viral infections, lit-
tle information is available on the direct role of oxidant
stress in HIVAN.
It remains to be determined whether nonviral actions
of PIs modulate HIVAN, and if so, whether the effect
ultimately promotes or impedes renal recovery. The net
outcome will be influenced by the role of apoptosis in
eliminating virus, a key host defense mechanism judging
by the ingenious mechanisms exploited by HIV to evade
it. Up to 50% of patients taking a PI-containing HAART
regimen stop or switch because of adverse events or dos-
ing complexity, prompting trials with PI-sparing regimens
and development of new PI compounds. Renal function
under the influence of these alternative regimens war-
rants close attention.
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